iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $44.00 by Analysts at HC Wainwright

Posted by on Aug 13th, 2023

iTeos Therapeutics (NASDAQ:ITOS – Free Report) had its price target cut by HC Wainwright from $54.00 to $44.00 in a report released on Wednesday, Marketbeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for iTeos Therapeutics’ Q3 2023 earnings at ($1.27) EPS, Q4 2023 earnings at ($1.35) EPS, FY2023 earnings at ($4.08) EPS, Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.46) EPS, Q3 2024 earnings at ($1.59) EPS, Q4 2024 earnings at ($1.72) EPS and FY2024 earnings at ($6.18) EPS.

Separately, Wedbush reaffirmed an outperform rating and set a $33.00 price target on shares of iTeos Therapeutics in a research report on Tuesday, August 8th.

Read Our Latest Stock Report on iTeos Therapeutics

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $12.05 on Wednesday. iTeos Therapeutics has a 1 year low of $11.75 and a 1 year high of $26.12. The business has a 50 day simple moving average of $13.77 and a two-hundred day simple moving average of $15.20. The firm has a market capitalization of $431.15 million, a PE ratio of -15.06 and a beta of 1.17.

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last posted its earnings results on Wednesday, May 10th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.55. The company had revenue of $12.60 million during the quarter, compared to analyst estimates of $13.80 million. iTeos Therapeutics had a negative return on equity of 4.42% and a net margin of 9.02%. Equities research analysts expect that iTeos Therapeutics will post -3.26 EPS for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd bought a new position in shares of iTeos Therapeutics in the 1st quarter worth about $67,000. Quadrant Capital Group LLC grew its position in iTeos Therapeutics by 9,041.7% in the second quarter. Quadrant Capital Group LLC now owns 2,194 shares of the company’s stock worth $29,000 after acquiring an additional 2,170 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of iTeos Therapeutics in the first quarter worth $73,000. James Investment Research Inc. acquired a new position in iTeos Therapeutics during the 1st quarter valued at $36,000. Finally, Quantbot Technologies LP acquired a new position in shares of iTeos Therapeutics in the 2nd quarter valued at $69,000.

iTeos Therapeutics Company Profile

(Get Free Report)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Recommended Stories

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.